Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMaud D’AveniJBJacques‐Olivier BayCBClaude-Éric Bulabois

Discussion

Loading...

Member takes

Overview

Analysis finds PTCy reduces severe GVHD incidence compared to ATG in AML patients undergoing stem cell transplants, suggesting improved outcomes.

Key Points

  • To compare the efficacy of post-transplant cyclophosphamide and anti-thymocyte globulin in preventing graft-versus-host disease in patients undergoing allogeneic stem cell transplantation.
  • Retrospective analysis of 3702 patients from the SFGM-TC registry.
  • Patients underwent first allo-HCT for acute myeloid leukemia or myelodysplastic syndromes from related and unrelated donors.
  • Comparison of GVHD prophylaxis strategies including PTCy, ATG, and no immunosuppressive agents.
  • At day 100, grade ≥ II aGVHD was 26% for PTCy and 29% for ATG, not significantly different.
  • At 2 years, moderate-severe chronic GVHD incidence was lower in PTCy group (14%) compared to ATG (19%).
  • PTCy reduced non-relapse mortality significantly compared to the group with no immunosuppressive agents.

Cite This Study

D’Aveni et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1efhttps://doi.org/10.1182/blood-2025-2450
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation2024 · 44 citations
  2. 2Unrelated donor transplantation with post-transplant cyclophosphamide versus ATG for myelodysplastic neoplasms2024 · 5 citations
  3. 3Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants2025
  4. 4Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation2025 · 1 citations
  5. 5ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?2024 · 36 citations